Site
Client
proxystylesheet
Output
Search
allAreas
However, we recognize that organizations face a number of hurdles in realizing these benefits due to the lack of trustworthy biomarkers data and standards in the public domain.
By drawing on the experience and knowledge of scientists in Prous Science, a Thomson Reuters business, as well as extensive participation of external experts, Thomson Reuters is uniquely placed to establish and develop these standards, and to provide trusted, authoritative biomarker information.
To find out more on BIOMARKERcenter and to receive complimentary copies of our Biomarkers Pharma Matters White Papers, please complete the form below.
*Indicates required field
Biomarkers: An indispensable addition to the drug development toolkit
Establishing the standards in biomarkers research
Salutation --None-- Dhr Dir Dr Dra Frau Herr Ing Inga Lic Miss MMe Monsieur Mr Mrs Ms Mtra Prof Signora Signore Sr Sra Srta
First Name*
Last Name*
Job Title
Company*
Email*
Phone
Address
City
State/Province (North America) - Select State/Province - AB BC MB NB NF NS NT ON PE QC SK YT AK AL AR AS AZ CA CO CT DC DE FL GA GU HI IA ID IL IN KS KY LA MA MD ME MI MN MO MS MT NC ND NE NH NJ NM NV NY OH OK OR PA PR RI SC SD TN TX UT VA VI VT WA WI WV WY
Zip/Postal Code
Country* - Select Country - ------------------------------ United States United Kingdom ------------------------------ Afghanistan Albania Algeria American Samoa Andorra Angola Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Botswana Brazil British Virgin Islands Brunei Bulgaria Burkfaso Burma Burundi Cambodia Cameroon Canada Cayman Islands Central African Republic Chad Chile Colombia Comoros Costa Rica Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Fiji Finland French Guiana France French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guinea Guyana Haiti Herzegovina Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Ivory Coast Jamaica Japan Jordan Kampuchea Kazakhstan Kenya Kirghizstan Kiribati Kuwait Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxemborg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mexico Micronesia Moldavia Monaco Mongolia Montenegro Morroco Mozambique Myanmar Namibia Nauru Nepal Nether Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Norway Oman P.R. China Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Rep. Congo Reunion Romania Russia Rwanda St. Lucia Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somolia South Africa South Korea Spain Sri Lanka St. Kitts St. Vincent Islands Sudan Suriname Swaziland Sweden Switzerland Syria Taiwan, R.O.C. Tajikistan Tanzania Thailand The Netherlands Togo Tonga Trinidad Tunisia Turkey Turkmen Tuvalu Uganda Ukraine United Arab Emirates United Kindgom Uruguay USA Uzbekistan Vanuatu Venezuela Vietnam West Samoa Yemen Yugoslavia Zaire Dem. Rep. Congo Zambia Zimbabwe
Industry* - Select Industry - End User Institutional Tech Transfer Bioinformatics BioPharma Consulting Environment / Waste Mgmt Food/Drink/Tobacco Genomics Incubator Company Agriculture/Crop Protection Cosmetics Household/Consumer General Fine Chemicals Other Performance/Specialty Petrochemicals Plastics/Polymers Aerospace and Defence Automotive and Transport Civil Engineering Electrical and Power Eng IT Hardware/Software Mechanical Engineering Medical Devices/Lab Equip Metallurgy/Materials Telecommunications Banking/Accounting Venture Capital End User Institutional Animal Health Big Pharma Consumer Products Contract Labs Diagnostics Generic Drugs Traditional Pharma Consulting Financial Legal Patent Library Patent Office Venture Capital Non Profit Other/To be determined Private individual Subscription Agency
Comments
In this white paper, we explore the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents. The potential of biomarkers to improve decision making, accelerate drug development and reduce development costs is discussed with insight from experts in industry and academia.
In this white paper, we show how the pharmaceutical industry is already beginning to rely on biomarker information, and explain how important it is to establish the standards that will support increasing biomarker implementation in the future.
When you submit this form we will send you a confirmation email that includes a link to a Profile Center. You can visit the Profile Center to select your preferences for receiving emails containing product information, newsletters, event invitations and more. You can also opt out of further communications if you choose.
View our privacy policy.
